Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes

被引：1
|
作者：
Rizzo, A. [1 ]
Rinaldi, L. [1 ]
Massafra, R. [1 ]
Cusmai, A. [1 ]
Guven, D. C. [2 ]
La Forgia, D. [1 ]
Latorre, A. [1 ]
Giotta, F. [1 ]
机构：
[1] Ist Tumori Bari Giovanni Paolo II IRCCS, Oncol Inst, Bari, Italy
[2] Hacettepe Univ, Dept Med Oncol, Oncol Hosp, Ankara, Turkiye
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412P
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [1] Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes
    Rizzo, Alessandro
    Rinaldi, Lucia
    Massafra, Raffaella
    Cusmai, Antonio
    Guven, Deniz Can
    Forgia, Daniele La
    Latorre, Agnese
    Giotta, Francesco
    FUTURE ONCOLOGY, 2024, 20 (20) : 1427 - 1434
  • [2] Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
    Dacoregio, Maria Inez
    Michelon, Isabella
    Castro, Caio Ernesto do Rego
    de Moraes, Francisco Cezar Aquino
    de Almeida, Guilherme Rossato
    Ravani, Lis Victoria
    Vilbert, Maysa
    Costa, Ricardo Lima Barros
    BREAST, 2025, 79
  • [3] Sacituzumab Govitecan in Metastatic Breast Cancer
    Ganguly, Shuvadeep
    Gogia, Ajay
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [4] Sacituzumab-govitecan in metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 16 - 16
  • [5] Sacituzumab Govitecan Toxicity Outcomes In Arab Patients with Metastatic Breast Cancer
    Altarturi, Maymouna
    Suleman, Kausar
    AlSayed, Adhar
    Al-Shamsi, Humaid
    Alawadhi, Aydah
    Basuliamn, Bassam
    Alaklabi, Sabah
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Sacituzumab Govitecan-Hziy as treatment in metastatic breast cancer: a systematic review and meta-analysis of RCTs
    Liem, J. Andrina
    Wijovi, F.
    Herijanto, B. E.
    Gracia, J. L.
    Rustiadi, N. D. D.
    Julian, L.
    Sucahyo, E. C. K.
    Argo, T. M.
    Glory, H.
    Sugianto, J. O.
    Jhoputri, C. F.
    Rubismo, K. Y.
    Wirawan, G. R.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1358 - S1358
  • [7] Sacituzumab Govitecan in Metastatic Breast Cancer REPLY
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [8] Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
    Cher, Boon Piang
    Goh, Sharon
    Aziz, Mohamed Ismail Abdul
    Wong, Grace
    Hui, Raymond Ng Chee
    Ong, Benjamin Shao-Kiat
    Ng, Kwong-Hoe
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (02) : 217 - 225
  • [9] Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.
    Dacoregio, Maria Inez
    Michelon, Isabella
    Castro, Caio
    Moraes, Francisco Cezar A.
    Ravani, Lis Victoria
    de Almeida, Guilherme Rossato
    Vilbert, Maysa
    Costa, Ricardo L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
    Lang, Yitian
    Chai, Qingqing
    Tao, Wenqi
    Liao, Yahui
    Liu, Xiaoyan
    Wu, Bin
    BREAST, 2023, 68 : 173 - 180
12345